Background <p>A significant number of newly developed drugs exhibit poor water solubility, resulting in limited bioavailability and reduced therapeutic effectiveness. Conventional solubility enhancement techniques often prove insufficient, particularly for drugs with low solubility in both aqueous and non-aqueous media. Nanosuspension technology has emerged as a promising strategy to overcome these limitations and improve drug delivery.</p> Objective <p>To develop and evaluate a hybrid nanosuspension containing Pioglitazone Hydrochloride and Teneligliptin for enhanced solubility, bioavailability, and therapeutic efficacy in antidiabetic treatment.Methods:A combined nanosuspension of Pioglitazone Hydrochloride and Teneligliptin was prepared and characterized. The formulations were evaluated for physical appearance, redispersibility, viscosity, pH, drug content, particle size, entrapment efficiency, and in vitro drug release. Stability studies were also conducted to assess the formulation's robustness over time.</p> Results <p>Among the prepared formulations, formulation F4 was identified as the optimized batch. It exhibited a particle size of 337 nm, viscosity of 1.02 cps, entrapment efficiency of 97%, and drug content of 99%. The formulation achieved 98% in vitro drug release, indicating enhanced dissolution performance. Stability studies demonstrated that the nanosuspension remained stable throughout the evaluation period without significant changes in its physicochemical properties.</p> Conclusion <p>The developed hybrid nanosuspension of Pioglitazone Hydrochloride and Teneligliptin successfully improved key formulation characteristics and demonstrated excellent drug release and stability. This combined nanosuspension approach represents a commercially feasible and cost-effective strategy for enhancing the bioavailability and therapeutic efficacy of antidiabetic drugs.</p>